CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5707-5716

  Winkler, Ashley E ^a   Brotman, Joshua J ^a   Pittman, Meredith E ^a   Judd, Nancy P ^a   Lewis Jr , James S ^a   Schreiber, Robert D ^a   Uppaluri, Ravindra ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INCIDENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; EPIDERMIS CELL; FETUS; GENE DELETION; HUMAN; HUMAN CELL; KERATINOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN INFLAMMATION; SKIN SQUAMOUS CELL CARCINOMA; SKIN TUMOR; SKINFOLD THICKNESS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMIS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; METHYLCHOLANTHRENE; MICE; MICE, MUTANT STRAINS; RECEPTORS, CXCR3; SKIN NEOPLASMS; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE;

EID: 80052212385     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0907     Document Type: Article

References (49)

1. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928. (Pubitemid 38680444)
2. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970-80.
3. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-15.
4. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996;93:13791-6. (Pubitemid 26424199)
5. Yang J, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004;9:846-55. (Pubitemid 38878130)
6. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-43. (Pubitemid 27172547)
7. Coughlin CM,Salhany KE,Gee MS, LaTemple DC,Kotenko S,Ma X, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34. (Pubitemid 28361292)
8. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
9. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-63. (Pubitemid 32288543)
10. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
11. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982;55:329-33. (Pubitemid 13119667)
12. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60. (Pubitemid 38680426)
13. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61. (Pubitemid 28293291)
14. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008;105:652-6. (Pubitemid 351171763)
15. Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, et al. The distinct contributions of murine T cell receptor (TCR) gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003;198:747-55. (Pubitemid 37087774)
16. Kwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH, Galan A, et al. Molecular analysis of tumor-promoting CD8+ T cells in twostage cutaneous chemical carcinogenesis. J Invest Dermatol 2010; 130:1726-36.
17. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401. (Pubitemid 34651385)
18. Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205:275-85. (Pubitemid 351281593)
19. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008;222:145-54. (Pubitemid 351430362)
20. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000;192:1515-20.
21. Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, et al. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A 2007;104:6770-5. (Pubitemid 47175576)
22. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003;198:433-42. (Pubitemid 36976054)
23. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006;66:7301-9. (Pubitemid 44197712)
24. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009;4:1350-62.
25. Sierro F, Biben C, Martínez-Muñoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007;104:14759-64. (Pubitemid 350003216)
26. Yates CC,Whaley D, Kulasekeran P,Hancock WW,Lu B,Bodnar R, et al. Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor.AmJ Pathol 2007;171:484-95. (Pubitemid 47344681)
27. Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B, et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation 2008;86:137-47.
28. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391: 344-5.
29. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83. (Pubitemid 28141661)
30. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010;70:490-500.
31. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009;182:6951-8.
32. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008;68:8437-45.
33. Shen H, Schuster R, Lu B, Waltz SE, Lentsch AB. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 2006;66:1721-8. (Pubitemid 44893898)
34. Nagpal ML, Davis J, Lin T. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta 2006;1762:811-8.
35. Wenzel J, Lucas S, Zahn S, Mikus S, Metze D, Ständer S, et al. CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graftversus- host disease. J Am Acad Dermatol 2008;58:437-42. (Pubitemid 351226304)
36. Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, Arreaza M, et al. Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2010;302:113-23.
37. Wenzel J, Tomiuk S, Zahn S, Küsters D, Vahsen A, Wiechert A, et al. Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer 2008;123:2605-15.
38. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31. (Pubitemid 29318619)
39. Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 2007;117:1884-92. (Pubitemid 47036322)
40. Cataisson C, Ohman R, Patel G, Pearson A, Tsien M, Jay S, et al. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 2009;69:319-28.
41. Lonsdorf AS, Hwang ST, Enk AH. Chemokine receptors in T-cellmediated diseases of the skin. J Invest Dermatol 2009;129:2552-66.
42. Luster AD, Cardiff RD, MacLean JA, Crowe K, Granstein RD. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Am Physicians 1998;110:183-96. (Pubitemid 28235170)
43. Yates CC, Krishna P, Whaley D, Bodnar R, Turner T, Wells A. Lack of CXC chemokine receptor 3 signaling leads to hypertrophic and hypercellular scarring. Am J Pathol 2010;176:1743-55.
44. Yusuf N, Nasti TH, Katiyar SK, Jacobs MK, Seibert MD, Ginsburg AC, et al. Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz (a)anthracene cutaneous carcinogenesis. Cancer Res 2008;68:3924-30.
45. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010;70:10112-20.
46. Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z. IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 2009;69:2010-7.
47. Thomas-Ahner JM, Wulff BC, Tober KL, Kusewitt DF, Riggenbach JA, Oberyszyn TM. Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage. Cancer Res 2007;67:3468-74. (Pubitemid 46724888)
48. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science 2007;317:121-4. (Pubitemid 47056470)
49. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-9. (Pubitemid 47076470)